NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 43

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016', provides in depth analysis on NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted pipeline therapeutics.

The report provides comprehensive information on the NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.)

  • The report reviews NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics and enlists all their major and minor projects

  • The report assesses NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) Overview 6
Therapeutics Development 7
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Products under Development by Stage of Development 7
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Products under Development by Therapy Area 8
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Products under Development by Indication 9
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Products under Development by Companies 12
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Companies Involved in Therapeutics Development 18
GenKyoTex S.A. 18
Glucox Biotech AB 19
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Drug Profiles 20
GKT-136901 - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
GKT-831 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Small Molecule to Inhibit NOX-4 for Endothelial Dysfunction - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Small Molecule to Inhibit NOX-4 for Heart Failure - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecule to Inhibit NOX-4 for Type-2 Diabetes - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Dormant Projects 31
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Featured News & Press Releases 32
Nov 11, 2015: Genkyotex's GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis 32
Sep 09, 2015: Genkyotex Announces Top-Line Results of Phase 2 Clinical Program 32
Jul 30, 2015: Genkyotex's NOX1&4 Inhibitor Strategy in Liver Fibrosis Supported by New Preclinical Results 33
Nov 13, 2014: Genkyotex Completes Enrollment into Phase 2 Trial of NOX1&4 Inhibitor GKT137831 in Diabetic Nephropathy 33
Apr 10, 2014: Genkyotex's GKT137831 Found to Reverse Fibrosis and Improve Survival in a Model of Persistent Lung Fibrosis 34
Nov 11, 2013: Genkyotex NOX Inhibitor GKT137831 Successfully Shown to Halt Diabetic Kidney Disease 35
Nov 05, 2013: Genkyotex Initiates Multinational Phase II Study with First in Class NOX Inhibitor GKT137831 in Diabetic Nephropathy Patients 36
Oct 21, 2013: Genkyotex Collaborators Elucidate Role of NOX4 in Osteoporosis 36
Sep 09, 2013: Genkyotex Receives FDA IND Approval for Phase II Clinical Study with First in Class NOX Inhibitor GKT137831 37
May 07, 2013: Genkyotex Collaborators Discover Role of NOX in Development of Atherosclerosis in Diabetic Mice 38
Nov 02, 2012: Genkyotex Presents Phase I Data On NOX Inhibitor GKT137831 At Kidney Week 2012 39
Oct 15, 2012: Genkyotex Announces Presentation Of Data From Phase I Studies Of GKT137831 At Kidney Week 2012 39
Aug 07, 2012: New Drug Successfully Halts Fibrosis In Animal Model Of Liver Disease, Study Reports 40
Jun 22, 2012: Genkyotex Announces Successful Phase Ia Data With GKT137831 40
Oct 31, 2011: GenKyoTex Starts Phase I Trial With NOX Inhibitor GKT137831 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 16
Number of Products by Stage and Molecule Type, H2 2016 17
Pipeline by GenKyoTex S.A., H2 2016 18
Pipeline by Glucox Biotech AB, H2 2016 19
Dormant Projects, H2 2016 31

List of Figures

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Top 10 Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Routes of Administration, H2 2016 16
Number of Products by Stage and Molecule Type, H2 2016 17
  • United States Industrial Enzymes Market Report 2016
    Published: 02-Dec-2016        Price: US 3800 Onwards        Pages: 108
    Notes: Sales, means the sales volume of Industrial Enzymes Revenue, means the sales value of Industrial Enzymes This report studies sales (consumption) of Industrial Enzymes in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Novozymes - Dupont - DSM - BASF - AB Enzymes - CHR.Hansen - Amano Enzyme Inc. - Soufflet Group - Dyadic Inter......
  • Global Pectinase Sales Market Report 2020
    Published: 01-Dec-2016        Price: US 4000 Onwards        Pages: 125
    This report studies sales (consumption) of Pectinase in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Novozymes - Genencor (DuPont) - Amano Enzyme - DSM - AB Enzymes - Verenium (BASF) - Shandong Longda - YSSH - Jinyuan - Sunson - Saide......
  • China DNA Polymerase Market Research Report 2016
    Published: 01-Dec-2016        Price: US 3200 Onwards        Pages: 122
    Notes: Sales, means the sales volume of DNA Polymerase Revenue, means the sales value of DNA Polymerase This report studies DNA Polymerase in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Thermo Fisher Scientific Inc. - GenScript - QIAGEN - Sigma-Aldrich Co. LLC. - Genomic Vision - Aidab Biotechnologies - Beijing Su......
  • Global Superoxide dismutase (SOD) Market Research Report 2016
    Published: 29-Nov-2016        Price: US 2900 Onwards        Pages: 101
    Notes: Production, means the output of Superoxide Dismutase (SOD) Revenue, means the sales value of Superoxide Dismutase (SOD) This report studies Superoxide Dismutase (SOD) in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering - Bionov - Worthington Biochemical Corporation......
  • Global Collagenase Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 28-Nov-2016        Price: US 3480 Onwards        Pages: 110
    Collagenase, obtained from Clostridium histolyticum, is an enzyme used for tissue dissociation in vitro and thus for isolation of many different types of cells. These isolated cells are then used for numerous clinical and research applications.Scope of the Report:This report focuses on the Collagenase in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regi......
  • United States Lipase Market Report 2016
    Published: 28-Nov-2016        Price: US 3800 Onwards        Pages: 110
    Notes: Sales, means the sales volume of Lipase Revenue, means the sales value of Lipase This report studies sales (consumption) of Lipase in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Advanced Enzymes - Amano Enzymes Inc. - Associated British Foods Plc - Chr. Hansen Holdings A/S - Clerici-Sacco Group - E. I. Du Pont De Nemours and Company (Genencor......
  • Alpha Glucosidase Inhibitors -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Alpha Glucosidase Inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Alpha Glucosidase Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, c......
  • GABA Transaminase Inhibitors -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "GABA Transaminase Inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the GABA Transaminase Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, c......
  • Plasminogen Activators -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Plasminogen Activators-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Plasminogen Activators. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaboration......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs